How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,865 results for

Imiquimod

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Imiquimod for the Treatment of Genital Warts: A Review of Clinical Effectiveness and Cost-Effectiveness

Imiquimod for the Treatment of Genital Warts: A Review of Clinical Effectiveness and Cost-Effectiveness Imiquimod for the Treatment of Genital Warts: A Review of Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need Imiquimod for the Treatment of Genital Warts: A Review of Clinical Effectiveness and Cost-Effectiveness Imiquimod for the Treatment of Genital Warts: A Review of Clinical Effectiveness and Cost-Effectiveness Published on: September 25, 2017 Project (...) Number: RC0930-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of imiquimod for the treatment of genital warts? What is the cost-effectiveness of imiquimod for the treatment of genital warts? Key Message Evidence from systematic reviews with low quality included studies suggests that overall for patients with anogenital warts (AGW) compared to placebo, treatment with imiquimod (IMQ) is associated

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

2. Imiquimod for the Treatment of Actinic Keratosis: A Review of Clinical and Cost-Effectiveness

Imiquimod for the Treatment of Actinic Keratosis: A Review of Clinical and Cost-Effectiveness Imiquimod for the Treatment of Actinic Keratosis: A Review of Clinical and Cost-Effectiveness | CADTH.ca Find the information you need Imiquimod for the Treatment of Actinic Keratosis: A Review of Clinical and Cost-Effectiveness Imiquimod for the Treatment of Actinic Keratosis: A Review of Clinical and Cost-Effectiveness Published on: September 15, 2017 Project Number: RC0929-000 Product Line: Research (...) Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of imiquimod for the treatment of actinic keratosis? What is the cost-effectiveness of imiquimod for the treatment of actinic keratosis? Key Message The three included systematic reviews showed that in patients with actinic keratosis (AK), treatment with imiquimod (IMQ) appeared to be better than placebo with respect to complete clearance.Few primary studies were available

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

3. Recurrence of vulval intraepithelial neoplasia following treatment with cidofovir or imiquimod: results from a multicentre, randomised, phase II trial (RT3VIN)

Recurrence of vulval intraepithelial neoplasia following treatment with cidofovir or imiquimod: results from a multicentre, randomised, phase II trial (RT3VIN) To compare the recurrence rates after complete response to topical treatment with either cidofovir or imiquimod for vulval intraepithelial neoplasia (VIN) 3.A prospective, open, randomised multicentre trial.32 general hospitals located in Wales and England.180 patients were randomised consecutively between 21 October 2009 and 11 January (...) 2013, 89 to cidofoovir (of whom 41 completely responded to treatment) and 91 to imiquimod (of whom 42 completely responded to treatment).After 24 weeks of treatment, complete responders were followed up at 6-monthly intervals for 24 months. At each visit, the Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was assessed and any new lesions were biopsied for histology.Time to histologically confirmed disease recurrence (any grade of VIN).The median length of follow up was 18.4 months

Full Text available with Trip Pro

2018 EvidenceUpdates

4. Imiquimod-induced psoriasis in mice depends on the IL-17 signaling of keratinocytes. (PubMed)

Imiquimod-induced psoriasis in mice depends on the IL-17 signaling of keratinocytes. The pathology of psoriasis strongly depends on IL-17A. Monoclonal antibodies blocking either the cytokine or its receptor are among the most efficient treatments for psoriatic patients. Keratinocytes can be activated upon exposure to IL-17A and tumor necrosis factor-α and secrete secondary cytokines and chemokines in the inflamed skin. In psoriasis and its imiquimod-induced mouse model, a strong skin (...) development. Only deletion of this receptor in keratinocytes reflected the full-body deletion of IL-17RA, resulting in strongly reduced dermatitis development. Imiquimod treatment of those IL-17 signaling-deficient mice maintained high monocytic infiltration but failed to attract neutrophils into the skin. We conclude that keratinocytes are a critical cellular target for IL-17A-mediated neutrophil attraction and psoriasis development.Copyright © 2019 The Authors. Published by Elsevier Inc. All rights

2019 Journal of Investigative Dermatology

5. Impact of smoking on imiquimod response in patients with vulval intraepithelial neoplasia. (PubMed)

Impact of smoking on imiquimod response in patients with vulval intraepithelial neoplasia. Vulval intraepithelial neoplasia (VIN) is a precancerous condition that may progress to invasive malignancy. VIN is associated with human papillomavirus (HPV) infection in most cases, and with inflammatory skin disorders in a smaller proportion of patients. Treatment of VIN has traditionally been surgical excision; however, topical treatments, including imiquimod cream, are becoming increasingly used (...) . Patient factors influencing response to imiquimod therapy, in particular smoking, have not yet been published.To assess the impact of smoking and other patient characteristics that may influence the treatment response to topical imiquimod for VIN.This was a retrospective cohort study of 46 women treated with topical imiquimod for VIN in a single centre dermatology unit from January 2011 to July 2017.Complete clinical resolution of VIN was observed in 28 of 46 patients (61%), but was significantly

2019 Clinical & Experimental Dermatology

6. Photothermal therapy enhanced the effectiveness of imiquimod against refractory cutaneous warts through boosting immune responses. (PubMed)

Photothermal therapy enhanced the effectiveness of imiquimod against refractory cutaneous warts through boosting immune responses. Refractory cutaneous warts are difficult to eliminate. In situ photo-immunotherapy (ISPI) is an innovative treatment concept combining local photothermal therapy (PTT) and topical immunotherapy using imiquimod. To compare the efficacy of ISPI vs topical imiquimod alone, a prospective randomized controlled trial was performed with patients suffering from refractory (...) cutaneous warts. In both groups, approximately 50% of the skin surface containing warts was treated for 6 weeks. On the basis of topical imiquimod, ISPI includes an additional 808 nm laser irradiation. Treatment response, temperatures during irradiation and histopathologic examination were evaluated. The complete response rate in the ISPI-group (22/36, 61.1%) was significantly higher than in the imiquimod alone group (11/34, 32.4%). In the ISPI-group, the mean maximum temperature was 44.5 ± 5.1°C

2019 Journal of biophotonics

7. Correction: PAMs ameliorates the imiquimod-induced psoriasis-like skin disease in mice by inhibition of translocation of NF-κB and production of inflammatory cytokines. (PubMed)

Correction: PAMs ameliorates the imiquimod-induced psoriasis-like skin disease in mice by inhibition of translocation of NF-κB and production of inflammatory cytokines. [This corrects the article DOI: 10.1371/journal.pone.0176823.].

Full Text available with Trip Pro

2018 PLoS ONE

8. Imiquimod 3.75% for field-directed therapy of actinic keratosis: results of a prospective case-series study in Greece. (PubMed)

Imiquimod 3.75% for field-directed therapy of actinic keratosis: results of a prospective case-series study in Greece. Imiquimod 3.75% is a field-directed treatment for actinic keratosis that can detect and treat clinical and subclinical lesions across an entire sun-exposed field. The detection of subclinical lesions is evidenced by an increase in lesions to the maximum lesion count during treatment (Lmax ). We report clinical outcomes for the first 15 patients treated with imiquimod 3.75 (...) % in daily clinical practice in Greece.Fifteen patients with actinic keratosis lesions were treated with imiquimod 3.75% in an outpatient setting in two 2-week treatment cycles separated by a 2-week treatment-free interval. Actinic keratosis lesions were counted before treatment, at the end of the first treatment cycle (Week 2; Lmax ), and 2 weeks after the second treatment cycle (Week 8). Local skin reactions (LSR) were also evaluated at Weeks 2 and 8.The median baseline actinic keratosis lesion count

2019 International Journal of Dermatology

9. Efficacy of topical Imiquimod 3.75% in the treatment of Actinic Keratosis of the scalp in immunosuppressed patients: our case series. (PubMed)

Efficacy of topical Imiquimod 3.75% in the treatment of Actinic Keratosis of the scalp in immunosuppressed patients: our case series. Actinic keratoses (AK) represent common cutaneous lesions, appearing in "Field cancerization areas" and potentially evolving towards invasive neoplasm. Immunosuppressed patients frequently develop numerous and aggressive AKs.In this observational study, we report our experience with topical Imiquimod 3.75% as "Field-directed therapy" in a cohort (...) of immunosuppressed patients.A group of 13 immunosuppressed patients presenting multiple AKs of the balding scalp was treated with topical Imiquimod 3.75%. Each patient underwent clinical examination at fixed timepoints during the treatment (T0, T14, T28, T42) and eight weeks after the end.In our cohort, the treatment was well tolerated, with minimal local adverse events. We observed a good clinical response, in terms of Lmax lesions (maximum lesion count during the course of therapy) and of AK clearance. In our

2019 Journal of Dermatological Treatment

10. Long-term outcomes of imiquimod-treated lentigo maligna. (PubMed)

Long-term outcomes of imiquimod-treated lentigo maligna. Lentigo maligna (LM) may be disfiguring and can progress to LM melanoma. Surgical excision remains the mainstay of treatment, but may result in disfigurement when used for large facial lesions. Topical imiquimod is a nonsurgical alternative although data on its long-term efficacy remain limited.To assess long-term outcomes of LM treated with imiquimod cream.We collected data retrospectively for 33 patients treated with imiquimod cream (...) for biopsy-proven LM from 2001 to 2016. Patients initially applied imiquimod once daily, 5 days/week for 6 weeks, aiming to produce a brisk local inflammatory response. If there was no response, the dose was increased to twice daily 7 days/week for 6 weeks and if again there was no response, to twice daily for 10 weeks.An inflammatory response developed in 29 (88%) of the 33 patients, and of these, 4 patients stopped treatment earlier than planned because they could not tolerate the inflammatory reaction

2019 Clinical & Experimental Dermatology

11. Imiquimod-induced skin inflammation is relieved by knockdown of sodium channel Na<sub>x</sub>. (PubMed)

Imiquimod-induced skin inflammation is relieved by knockdown of sodium channel Nax. Nax is an atypical sodium channel that mediates inflammatory pathways in pathological conditions of the skin. In this study, we developed a skin inflammation model in the rabbit ear through application of imiquimod (IMQ). Knockdown of Nax using RNAi attenuated IMQ-induced skin inflammation, including skin erythema, scaling, and papule formation. Histologic analysis showed that thickening

2019 Experimental Dermatology

12. Effectiveness of 5% Topical Imiquimod for Lentigo Maligna Treatment. (PubMed)

Effectiveness of 5% Topical Imiquimod for Lentigo Maligna Treatment. Lentigo maligna (LM) is treated to prevent progression to lentigo maligna melanoma (LMM). Surgery is the gold standard but an alternative treatment is off-label topical imiquimod. The aim of this study was to evaluate the effectiveness of 5% topical imiquimod treatment for lentigo maligna. In the period 2007-2017 57 patients with lentigo maligna were treated with off-label topical imiquimod once daily for 12 weeks. Complete (...) clinical clearance was observed in 48 patients (84.2%) and partial clearance in 3 patients (5.3%). Three patients (5.3%) showed no response and another 3 patients (5.3%) stopped treatment due to side-effects. After 4.5 years during follow-up one patient developed a lentigo maligna melanoma which was subsequently excised. Treatment with topical imiquimod resulted in complete clearance of lentigo maligna in 48 out of 57 patients (84.2%). Topical imiquimod is an acceptable treatment option for patients

Full Text available with Trip Pro

2019 Acta Dermato-Venereologica

13. Use of topical imiquimod in the treatment of VIN: a case report and review of the literature (PubMed)

Use of topical imiquimod in the treatment of VIN: a case report and review of the literature Vulvar intraepithelial neoplasia (VIN) is a premalignant disease of the vulvar squamous epithelium. Standard treatment for VIN lesions is surgical excision. Alternative therapeutic options for conservative treatment have been sought by patients to prevent disfigurement and to preserve sexual function. We present such a patient in whom topical imiquimod was used with a successful outcome. Imiquimod

Full Text available with Trip Pro

2016 International journal of women's dermatology

14. Imiquimod for the Treatment of External Genital Warts in Adults: Clinical and Cost-effectiveness

Imiquimod for the Treatment of External Genital Warts in Adults: Clinical and Cost-effectiveness Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid (...) of research or private study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Imiquimod for the Treatment

2013 Canadian Agency for Drugs and Technologies in Health - Rapid Review

15. Development of Vitiligo-Like Depigmentation after Treatment of Lentigo Maligna Melanoma with 5% Imiquimod Cream (PubMed)

Development of Vitiligo-Like Depigmentation after Treatment of Lentigo Maligna Melanoma with 5% Imiquimod Cream A 69-year-old man presented with a black irregular patch on his left cheek. Skin biopsy revealed lentigo maligna melanoma in situ. He was treated via partial excision of the melanoma, followed by the application of 5% imiquimod cream every other night for 6 to 8 hours. The patient experienced severe local inflammation accompanied by burning, edema, and erythema, as well as oozing (...) and crusting. The patient discontinued using the imiquimod cream after 15 applications because of the inflammation. Depigmentation was noted in the treated area 3 months after the initiation of treatment with imiquimod cream. Histological examination using Melan-A staining of the depigmented area revealed an absence of melanocytes, which is consistent with vitiligo. The depigmented lesions improved considerably after a 5-year follow-up, and there was no recurrence of melanoma.

Full Text available with Trip Pro

2018 Annals of dermatology

16. Differential Effects of Digoxin on Imiquimod-Induced Psoriasis-Like Skin Inflammation on the Ear and Back (PubMed)

Differential Effects of Digoxin on Imiquimod-Induced Psoriasis-Like Skin Inflammation on the Ear and Back 30065596 2018 11 14 1013-9087 30 4 2018 Aug Annals of dermatology Ann Dermatol Differential Effects of Digoxin on Imiquimod-Induced Psoriasis-Like Skin Inflammation on the Ear and Back. 485-488 10.5021/ad.2018.30.4.485 Madsen Marie M https://orcid.org/0000-0001-6579-9376 Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark. Pedersen Tanja Xenia TX Department

Full Text available with Trip Pro

2018 Annals of dermatology

17. Chitosan-based nanoformulated (−)-epigallocatechin-3-gallate (EGCG) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis (PubMed)

Chitosan-based nanoformulated (−)-epigallocatechin-3-gallate (EGCG) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis Psoriasis is a chronic and currently incurable inflammatory skin disease characterized by hyperproliferation, aberrant differentiation, and inflammation, leading to disrupted skin barrier function. The use of natural agents that can abrogate these effects could be useful for the treatment of psoriasis. Earlier (...) nanoEGCG) suitable for topical delivery for treating psoriasis. We investigated and compared the efficacy of nanoEGCG versus native or free EGCG in vitro and in an in vivo imiquimod (IMQ)-induced murine psoriasis-like dermatitis model. The in vivo relevance and efficacy of nanoEGCG formulation (48 µg/mouse) were assessed in an IMQ-induced mouse psoriasis-like skin lesion model compared to free EGCG (1 mg/mouse).Like free EGCG, nanoEGCG treatment induced differentiation, and decreased proliferation

Full Text available with Trip Pro

2018 International journal of nanomedicine

18. A Pilot Study of the Immunologic, Virologic, and Pathologic Consequences of Intra-Anal 5% Imiquimod in HIV-1-Infected Men With High-Grade Squamous Intraepithelial Lesions. (PubMed)

A Pilot Study of the Immunologic, Virologic, and Pathologic Consequences of Intra-Anal 5% Imiquimod in HIV-1-Infected Men With High-Grade Squamous Intraepithelial Lesions. Imiquimod can be used to treat internal anal high-grade squamous intraepithelial lesions. In HIV-1-infected individuals there is a theoretical concern for increased HIV replication in anorectal tissue secondary to imiquimod-induced mucosal inflammation.The purpose of this study was to assess local virologic, immunologic (...) , and pathologic effects of imiquimod treatment in HIV-infected individuals.This was a pilot study at a single academic center.The study was conducted at the University of Pittsburgh Anal Dysplasia Clinic.HIV-1-infected individuals with biopsy-confirmed internal anal high-grade squamous intraepithelial lesions were included.Imiquimod cream was prescribed for intra-anal use 3 times per week for 9 weeks.Anal human papillomavirus typing, anal and rectal tissue HIV-1 RNA and DNA quantification, cytokine gene

2018 Diseases of the Colon & Rectum

19. Reversed actinic damage in two children with xeroderma pigmentosum treated with topical imiquimod. (PubMed)

Reversed actinic damage in two children with xeroderma pigmentosum treated with topical imiquimod. 29377344 2018 06 26 1468-3083 32 7 2018 Jul Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol Reversed actinic damage in two children with xeroderma pigmentosum treated with topical imiquimod. e282-e284 10.1111/jdv.14818 Latour I I Hospital Infantil Universitario Niño Jesús, Menéndez Pelayo 65, 28009, Madrid, Spain. Hernández-Martín A A Hospital

2018 Journal of the European Academy of Dermatology and Venereology

20. Resident and monocyte-derived Langerhans cells are required for imiquimod-induced psoriasis-like dermatitis model. (PubMed)

Resident and monocyte-derived Langerhans cells are required for imiquimod-induced psoriasis-like dermatitis model. Langerhans cells (LCs) are dendritic cells that reside in the epidermis and local inflammation results in an increased differentiation of monocyte-derived LCs. Only few studies have investigated on the role of LCs in psoriasis-like dermatitis model, but the results are variable and the exact role of LCs in psoriasis model remains to be elucidated.To explore the functional role (...) of resident (rLCs) and monocyte-derived LCs (mLCs) in imiquimod (IMQ)-induced psoriasis-like inflammation using human Langerin-diphtheria toxin subunit A (huLang-DTA) mice.5% IMQ cream was topically applied on the skins. Clinical and histopathological features were evaluated. Psoriasis-related gene expression was analyzed by quantitative polymerase chain reaction. The production of psoriasis-related cytokines including IL-17A and IL-22 by T cells were assessed by flow cytometry from the lesional

2018 Journal of dermatological science

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>